Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Wong, Gabriel | - |
dc.contributor.author | Lee, Janet | - |
dc.contributor.author | Kim, Myung Hwa | - |
dc.contributor.author | Smith, Nathaniel | - |
dc.contributor.author | Blissett, Rob | - |
dc.contributor.author | Kim, Hyung Joon | - |
dc.date.available | 2020-08-04T03:20:32Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 0300-7995 | - |
dc.identifier.issn | 1473-4877 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/42840 | - |
dc.description.abstract | Background: Given a hepatitis C virus (HCV) elimination goal by 2030, World Health Organization (WHO) guidelines recommend scaling up HCV screening and treatment with highly-effective direct-acting antivirals (DAAs). This study investigated the cost-effectiveness of various screening and treatment strategies for chronic HCV patients in South Korea in patients aged over 40 as compared to currently screening only high-risk patients. Methods: A published Markov disease progression model was used with a screening/treatment decision-tree to model different screening and treatment strategies for Korean HCV patients (aged over 40) from a national payer perspective over a lifetime time horizon. The screening strategies included "screen-all" (upfront only: "once"; or upfront and age 65: "twice") or a "high-risk only" screening strategy followed by treatment. Treatment strategies included either ledipasvir/sofosbuvir (LDV/SOF), SOF + ribavirin (SOF + RBV; in GT2 only), or glecaprevir/pibrentasvir (GLE/PIB). Model inputs were sourced from published literature and costing databases and validated by Korean hepatologists. Results: Regardless of treatment strategy, a "screen all twice" scenario led to the lowest rates of advanced liver disease events compared to "screen all once" and "high-risk only" screening scenarios. In this screening scenario, treatment with LDV/SOF for GT1/2 dominates (i.e. is more effective and less4costly) LDV/SOF in GT1 and SOF + RBV in GT2, while GLE/PIB is not cost-effective relative to LDV/SOF (& x20a9;105,124,920/QALY) at a willingness-to-pay threshold of 1xGDP per capita. Conclusion: Screening all South Korean patients twice followed by LDV/SOF treatment is cost-effective as compared current high-risk screening. Adopting this strategy can help achieve WHO HCV elimination goals. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.title | Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea | - |
dc.type | Article | - |
dc.identifier.doi | 10.1080/03007995.2020.1756232 | - |
dc.identifier.bibliographicCitation | CURRENT MEDICAL RESEARCH AND OPINION, v.36, no.6, pp 993 - 1002 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000532175900001 | - |
dc.identifier.scopusid | 2-s2.0-85084481632 | - |
dc.citation.endPage | 1002 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 993 | - |
dc.citation.title | CURRENT MEDICAL RESEARCH AND OPINION | - |
dc.citation.volume | 36 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Hepatitis C | - |
dc.subject.keywordAuthor | cost-effectiveness | - |
dc.subject.keywordAuthor | cost-utility | - |
dc.subject.keywordAuthor | ledipasvir | - |
dc.subject.keywordAuthor | sofosbuvir | - |
dc.subject.keywordAuthor | glecaprevir | - |
dc.subject.keywordAuthor | pibrentasvir | - |
dc.subject.keywordAuthor | South Korea | - |
dc.subject.keywordPlus | VIRUS GENOTYPE 1 | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | GENERAL-POPULATION | - |
dc.subject.keywordPlus | PLUS RIBAVIRIN | - |
dc.subject.keywordPlus | FREE REGIMENS | - |
dc.subject.keywordPlus | SOUTH-KOREA | - |
dc.subject.keywordPlus | 6 INFECTION | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | PRODUCTIVITY | - |
dc.subject.keywordPlus | LEDIPASVIR/SOFOSBUVIR | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.